• 1
    VonRoemeling R, Hrushesky WJ. Principles of chemotherapy and immunotherapy for head neck cancer. In: Paparella MM, Shumrick DA, Gluckman JL, Meyerhoff WL, eds. Otolaryngology. Philadelphia: WB Saunders, 1991.
  • 2
    Gonzalez-Vitale JC, Hayes DM, Cvitkovic E, Sternberg SS. The renal pathology in clinical trials of cis-platinum (II) diamine dichloride. Cancer 1977; 39:13621371.
  • 3
    Hayes, DM, Cvitkovic E, Golbey R, Scheiner E, Helson L, Dradoff IH. high dose cis-platinum diamine dichloride amelioration of renal toxicity by mannitol diuresis. Cancer 1977; 39:13721381.
  • 4
    Strauss M, Towfighi J, Lipton A. Cis-platinum ototoxicity: clinical experience and temporal bone histopathology. Laryngoscope 1983; 93:15541559.
  • 5
    Schaefer S, Post JD, Close LG, Wright CG. Ototoxicity of low and moderate dose cis-platinum. Cancer 1985; 56:19341939.
  • 6
    Fleischman RW, Stadnidri SW, Ethier ML, Schaeppi U. Ototoxicity of cis-dichlorodiammino platinum (II) in the guinea pig. Toxicol Appl Pharm 1975; 33:320322.
  • 7
    Ihshiyama S, Nakayama I, Aku Da Y, Kawamura H, Kawaguchi H. Reduction of Dibekacin-induced nephrotoxicity. Presented at the 13th International Congress of Chemotherapy, Vienna, Austria, August 28-September 3, 1983.
  • 8
    Shiegeharu I, Tetsutaro N, Takeda U, Koeda T. Protective effect of fosfomycin on the experimental nephrotoxicity induced by Dibekacin. J Pharm Dyn 1982; 5:659669.
  • 9
    Viotte G, Morin JP, Bendirdjian JP, Ducastelle B, Godin M, Fillastre JP. The effects of increasing doses of fosfomycin, gentamicin, and their association on the rat kidney. Drugs Exp Clin Res 1980; 6:317324.
  • 10
    Neuman M. Protective effect of fosfomycin on the nephrotoxicity of amikacin. Presented at the 13th International Congress of Chemotherapy, Vienna, Austria, August 28-September 3, 1983.
  • 11
    Palmieri L, Cioni L, Puccini R, Schnoblingove Z. A study on reduced gentamicin nephrotoxicity and increased antibacterial action by a gentamicin-fosfomycin association in vitro and in vivo. Drugs Exp Clin Res 1983; 9:537543.
  • 12
    Schweitzer VG, Dolan DF, Abrams GE, Davidson T, Snyder R. Amelioration of cisplatin-induced ototoxicity by fosfomycin. Laryngoscope 1986; 96:948958.
  • 13
    Neuman M. Recent developments in the field of phosphoric acid antibiotics. J Antimicrob Chemother 1984; 14:309311.
  • 14
    Wagner T, Kreft B, Bohlmann G, Schwieder G. Effects of fosfomycin, Mensa, and sodium thiosulfate on the toxicity and antitumor activity of cisplatin. J Cancer Res Clin Oncol 1988; 114:497501.
  • 15
    Olson J, Truelson J, Street N. In vitro interaction of cisplatin and fosfomycin on squamous cell carcinoma cultures. Arch Otolaryngol 1994; 120:12531257.
  • 16
    Baker SR. An in vivo model for squamous cell carcinoma of the head and neck. Laryngoscope 1985; 95:4555.